First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Center for Drug Evaluation and Research
Indexed incrossrefpubmed
Abstract
In May 2017, the FDA approved pembrolizumab, a programmed death 1 inhibitor, for adult and pediatric patients with unresectable or metastatic, microsatellite-instability–high or mismatch-repair–deficient solid tumors, regardless of tumor site or histology.
Citation impact
656
total citations
- FWCI
- 43.32
- Percentile
- 100%
- References
- 5
Citations per year
Authors
3Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Microsatellite instability
- Food and drug administration
- Cancer
- Biomarker
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.